Momenta and Sandoz fail on US enoxaparin

Momenta and Sandoz face the prospect of paying treble damages to Amphastar over allegations the two firms “restricted trade and prevented competition in the manufacture and sale of generic enoxaparin” in the US, after a district judge denied Momenta’s bid to dismiss the US-based specialty company’s antitrust lawsuit.